Updates

April 3, 2020April 3, 2020
Winners Named for Prostate Cancer Foundation’s TRUE Love Awareness Contest

The 3rd annual TRUE Love Contest of the Prostate Cancer Foundation (PCF), which features inspirational stories from patients and caregivers to raise disease awareness, ... Read more
March 27, 2020March 27, 2020
Guidelines for Radiation Therapy with COVID-19 Urge Less Treatment

New guidelines for radiation oncologists suggest that, during the COVID-19 pandemic, interactions with healthcare professionals should be done remotely where possible, and treatments should be ... Read more
March 23, 2020March 23, 2020
Combining Two Biopsy Methods Improves PC Diagnosis, Study Shows

Combining two methods of prostate biopsy — using one guided by magnetic resonance imaging (MRI) along with conventional ultrasound-guided biopsy — results in a ... Read more
March 19, 2020March 23, 2020
Urine Biomarkers Can Be Used to Develop Test for Prostate Cancer, Study Finds

Patients with prostate cancer exhibit changes in the levels of some urinary molecules compared with people with benign prostate diseases and healthy individuals, a ... Read more
March 18, 2020March 18, 2020
Proscia and UCSF Partnering to Deliver AI Apps to Improve Cancer Diagnosis

Proscia and the University of California San Francisco (UCSF) are partnering to use artificial intelligence (AI) to improve the accuracy and speed of cancer ... Read more

News

Veru Advances Prostate Cancer Therapy VERU-111 to Phase 2 Portion of Trial
March 16, 2020March 23, 2020
Veru said it initiated the Phase 2 portion of a clinical trial testing the ...
News

Adoptive Cell Therapy Can Slow Prostate Cancer Growth, Study in Mice Reports
March 12, 2020March 12, 2020
Treating prostate cancer animal models with modified immune cells that were isolated from bone ...
News

Ciforadenant Has Promising Anti-tumor Activity in mCRPC, Early Data Show
March 11, 2020March 23, 2020
Treatment with Corvus Pharmaceuticals‘ ciforadenant (CPI-444), alone or in combination with Tecentriq (atezolizumab), is well ...
News

Prolaris Test Predicts Which PC Patients Benefit from Combo Therapy, Study Finds
March 9, 2020March 9, 2020
Myriad Genetics’ Prolaris — a genetic test that predicts the aggressiveness of prostate cancer ...
News

3 New miR Scientific Urine Tests Diagnose, Classify Prostate Cancer, Data Shows
March 6, 2020March 12, 2020
The bioscience company miR Scientific has presented breakthrough data on three urine-based tests to ...
News

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare
March 5, 2020March 5, 2020
In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media ...

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery
March 4, 2020March 4, 2020
A genetic test, called Decipher Prostate RP, can help to identify those prostate cancer patients with ...
“First patient in treatment for RhoVac’s clinical phase II study in Finland”
March 3, 2020March 23, 2020
Here’s some data from the prior trial: https://www.rhovac.com/cision/46DAAF83E44458D3/ https://www.prnewswire.com/news-releases/rhovac-reports-interim-results-on-immunological-response-with-rv001-300959779.html And the approval for trial ...
Statins, Metformin May Extend Survival in High-risk Prostate Cancer, Large Study Suggests
March 2, 2020March 2, 2020
Decipher GRID ‘Signature’ Predicts Chemo Benefits in HSPC, Research Shows
February 27, 2020February 27, 2020
High Vegetable Diet Does Not Halt Prostate Cancer, Study Finds
February 26, 2020February 26, 2020
Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows
February 24, 2020February 24, 2020

Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows
February 20, 2020February 20, 2020
Adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) ...
Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show
February 19, 2020February 19, 2020
eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest
February 17, 2020February 17, 2020
UPenn Researchers Awarded $500K Grant to Develop CAR T-cell Therapy for Advanced PC
February 12, 2020February 12, 2020

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show
February 11, 2020February 13, 2020
Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), ...
Concerto, Pfizer Expand Data Partnership to Include Prostate, Other Cancers
February 10, 2020February 10, 2020
Stony Brook Team Given $4.2M Grant to Expand Promising Work in Advanced Prostate Cancer
January 31, 2020February 14, 2020

News

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer
January 29, 2020January 30, 2020
The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to ...
News

First Patient Dosed in Early Trial Testing ORIC-101, Xtandi Combo for Metastatic Prostate Cancer
January 28, 2020February 3, 2020
A Phase 1b trial has started dosing patients to study whether Oric Pharmaceutical’s ORIC-101 ...
News

DNA Non-coding Regions Identified as Therapeutic Targets for Prostate Cancer, New Study Suggests
January 24, 2020February 5, 2020
Six regions in the non-coding parts of the DNA that surround FOXA1, a major ...
News

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo
January 23, 2020January 23, 2020
Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) ...
News

FDA OKs Phase 2b Trial on SUBA-Itraconazole for Metastatic Castration-resistant Prostate Cancer
January 22, 2020February 14, 2020
The U.S. Food and Drug Administration (FDA) has cleared a Phase 2b clinical trial ...
News

FDA Grants Priority Review to Lynparza as Treatment for Mutated Metastatic Castration-resistant Prostate Cancer
January 22, 2020January 22, 2020
The U.S. Food and Drug Administration (FDA) has granted priority review status to an application ...
News

Zuclomiphene Safely Eases Hot Flashes Linked to ADT Use, Phase 2 Trial Reports
January 20, 2020
Interim Phase 2 trial results show that Veru‘s experimental treatment zuclomiphene citrate is well-tolerated ...
News

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations
January 16, 2020January 16, 2020
The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) ...
News

Advaxis Seeks FDA Approval to Begin Phase 1 Trial of its ADXS-504 Immunotherapy for Prostate Cancer
January 15, 2020January 15, 2020
Advaxis is seeking permission from the U.S. Food and Drug Administration (FDA) to start ...
News

Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests
January 13, 2020January 13, 2020
Noxopharm’s Veyonda (idronoxil), in combination with low-dose radiation therapy, safely halted disease progression and eased ...
News

US Congress Increases Funding for Prostate Cancer Research for FY 2020
January 8, 2020
To foster more research projects in prostate cancer, the U.S. Congress has increased funding ...
News

EMA Committee Favors Extending Use of Erleada for Metastatic Castration-sensitive Prostate Cancer
January 6, 2020January 30, 2020
The Committee for Medicinal Products for Human Use recommends extending the use of Janssen’s ...
News

PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows
December 30, 2019January 9, 2020
Progenics Pharmaceuticals’ PyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect ...
News

Lynparza Particularly Effective in Prostate Cancer Patients Carrying BRCA Mutations, Phase 2 Study Shows
December 19, 2019December 19, 2019
Lynparza (olaparib), a breast and ovarian cancer treatment, is also showing promising results in ...
News

FDA Expands Xtandi Approval to Include Metastatic Castration-sensitive Prostate Cancers
December 18, 2019December 18, 2019
The U.S. Food and Drug Administration (FDA) has agreed to expand Xtandi‘s (enzalutamide) approval to ...
News

Prostate Cancer Campaigns Boost Enrollment in Study to Validate ClarityDX Diagnostic Test in Canada
December 16, 2019December 16, 2019
Campaigns by Movember and the Alberta Cancer Foundation have helped to raise the number ...
News

Blank Family Foundation Donates $1M to Mount Sinai for Prostate Cancer Research
December 12, 2019
The Arthur M. Blank Family Foundation has given $1 million to the Icahn School ...
News

Lower Prostate Cancer Risk in Diabetics Likely Due to Fewer Biopsies, Not Medications, Study Says
December 11, 2019
Common treatments for diabetes don’t appear to mask or reduce levels of a prostate ...

September 12, 2017September 12, 2017

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

News

Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European ... Read more

Subscribe to our mailing list

Pin It on Pinterest